mitoxantrone has been researched along with Blast Phase in 28 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and toxicity of carboplatin plus mitoxantrone in blast crisis of chronic myeloid leukemia (CMLBC) were evaluated." | 9.14 | A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. ( Dutcher, JP; Gaynor, B; Morris, EL; Paietta, E; Wiernik, PH, 2010) |
| "In an effort to determine if cell cycle active agents are augmented when given after non-cell cycle active agents, 104 patients with either multiply relapsed or refractory acute nonlymphocytic leukemia or blast crisis of chronic myelogenous leukemia were treated with mitoxantrone." | 9.07 | Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. ( Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R, 1993) |
| "Mitoxantrone, a new anthracenedione, was administered to thirty-nine patients with relapsed and refractory acute leukemia and to 12 patients with blastic crisis of chronic myelogenous leukemia between August 1981 and September 1984." | 7.67 | [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Kimura, I; Kitani, T; Masaoka, T; Meguro, S; Nagai, K; Ogawa, M; Ohnoshi, T; Sampi, K; Wakui, A; Yamada, K, 1986) |
| "To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML-MBC and its influence on bone marrow CD34+CD7+ cells." | 6.79 | Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. ( Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J, 2014) |
| "The efficacy and toxicity of carboplatin plus mitoxantrone in blast crisis of chronic myeloid leukemia (CMLBC) were evaluated." | 5.14 | A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia. ( Dutcher, JP; Gaynor, B; Morris, EL; Paietta, E; Wiernik, PH, 2010) |
| "Cytarabine is an essential drug for inducing remission of acute myelogenous leukemia, and it is also one the most effective drugs used as salvage therapy for patients with all types of relapsed acute leukemia." | 5.09 | A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. ( Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB, 1999) |
| "In an effort to determine if cell cycle active agents are augmented when given after non-cell cycle active agents, 104 patients with either multiply relapsed or refractory acute nonlymphocytic leukemia or blast crisis of chronic myelogenous leukemia were treated with mitoxantrone." | 5.07 | Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study. ( Bennett, J; Browman, G; Bryant, J; Goldberg, J; Grunwald, H; Gryn, J; Larson, R; Preisler, H; Raza, A; Vogler, R, 1993) |
| "In a phase I study, 68 patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), and accelerated- and blastic-phase CML received induction therapy consisting of cytarabine 3 g/m2 by infusion over 3 hours daily for 5 days, with escalating doses of mitoxantrone 40 to 80 mg/m2 over 1 to 2 days by intravenous infusion over 15 minutes." | 5.07 | Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. ( Ahmed, T; Alberts, DS; Arlin, Z; Baier, M; Baskind, P; Feldman, EJ; Mittelman, A; Peng, YM; Plezia, P, 1993) |
| "To evaluate the clinical relevance of multidrug resistance (MDR) phenotype, the intracellular daunorubicin accumulation (IDA) and P-glycoprotein (P-gp) expression were investigated in 87 adult patients with acute leukemia: 69 patients with de novo acute myeloid leukemia (AML), 10 with AML at relapse, and eight with secondary leukemia to myelodysplastic syndromes (MDS-AML)." | 3.69 | Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. ( Feldmann, L; Guerci, A; Guerci, O; Marchal, S; Merlin, JL; Missoum, N; Rose, C; Witz, F, 1995) |
| "In a phase II study, patients with chronic myelogenous leukemia in blast crisis (CML-BC) were treated with intravenous (IV) mitoxantrone (5 mg/m2 per day given over 30 min x 5 days and high-dose arabinosylcytosine (ara-C) (3 g/m2 IV q 12 h x 6)." | 3.67 | Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine. ( Heinemann, V; Meyn, RE; Murray, D; Plunkett, W; Walters, R, 1988) |
| "Mitoxantrone, a new anthracenedione, was administered to thirty-nine patients with relapsed and refractory acute leukemia and to 12 patients with blastic crisis of chronic myelogenous leukemia between August 1981 and September 1984." | 3.67 | [Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia]. ( Kimura, I; Kitani, T; Masaoka, T; Meguro, S; Nagai, K; Ogawa, M; Ohnoshi, T; Sampi, K; Wakui, A; Yamada, K, 1986) |
| "To explore the therapeutic effect of homoharringtonine (HHT) combined with cytarabine (HA regimen) on CML-MBC and its influence on bone marrow CD34+CD7+ cells." | 2.79 | Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells. ( Deng, Z; Ding, B; Li, Y; Shi, Y; Zho, J, 2014) |
| "Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methylprednisolone 1000 mg/day intravenously for 5 days." | 2.70 | Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone. ( Ayyildiz, O; Bolaman, Z; Demir, S; Kadiköylü, G; Köseoğlu, M; Müftüoğlu, E; Sönmez, HM, 2002) |
| "A phase II clinical study was performed to evaluate the effectiveness and toxicity of cladribine (2-CdA) combined with mitoxantrone (CM regimen) in the treatment of chronic myeloid leukemia in blastic phase (CML BP)." | 2.70 | Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia. ( Góra-Tybor, J; Robak, T, 2001) |
| "The prognosis of blast crisis (BC) of chronic myelogenous leukemia (CML) is extremely poor despite many efforts to induce remission with chemotherapy." | 2.40 | Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate. ( Chiba, S; Hirai, H; Honda, H; Kanda, Y; Yazaki, Y, 1999) |
| "We report a 20-month-old boy with acute lymphoblastic leukemia with the 11q23 translocation whose blasts markedly increased in peripheral blood after intravenous granulocyte colony-stimulating factor (G-CSF) administration, but disappeared after stopping G-CSF." | 1.30 | Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF. ( Goi, K; Iijima, K; Inukai, T; Kagami, K; Kinoshita, A; Kojika, S; Mori, T; Nakazawa, S; O-Koyama, T; Sugita, K; Suzuki, T; Tezuka, T, 1998) |
| "We measured the percentage of Philadelphia chromosome (Ph)-negative cells in the autologous cells collected after conventional-dose chemotherapy-induced myelosuppression before autologous transplant and in the marrow of these same CML patients after autologous transplantation of these cells into recipients treated with the cyclophosphamide, VP-16, and TBI." | 1.29 | Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog ( Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (17.86) | 18.7374 |
| 1990's | 14 (50.00) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 2 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 2 |
| Deng, Z | 1 |
| Zho, J | 1 |
| Ding, B | 1 |
| Shi, Y | 1 |
| Dutcher, JP | 2 |
| Morris, EL | 1 |
| Gaynor, B | 1 |
| Paietta, E | 2 |
| Wiernik, PH | 2 |
| Axdorph, U | 1 |
| Stenke, L | 1 |
| Grimfors, G | 1 |
| Carneskog, J | 1 |
| Hansen, J | 1 |
| Linder, O | 1 |
| Ljungman, P | 1 |
| Löfvenberg, E | 1 |
| Malm, C | 1 |
| Simonsson, B | 1 |
| Turesson, I | 1 |
| Vilén, L | 1 |
| Udén, AM | 1 |
| Björkholm, M | 2 |
| Bolaman, Z | 1 |
| Köseoğlu, M | 1 |
| Ayyildiz, O | 1 |
| Kadiköylü, G | 1 |
| Sönmez, HM | 1 |
| Demir, S | 1 |
| Müftüoğlu, E | 1 |
| Borker, A | 1 |
| Yu, L | 1 |
| Ode, D | 1 |
| Hiçsönmez, G | 1 |
| Cetin, M | 1 |
| Tuncer, AM | 1 |
| Yenicesu, I | 1 |
| Aslan, D | 1 |
| Ozyürek, E | 1 |
| Unal, S | 1 |
| Fiser, K | 1 |
| Klamová, H | 1 |
| Moravcová, J | 1 |
| Fruehauf, S | 1 |
| Topaly, J | 1 |
| Buss, EC | 1 |
| Fischer, T | 1 |
| Ottmann, OG | 1 |
| Emmerich, B | 1 |
| Müller, MC | 1 |
| Schuld, P | 1 |
| Balleisen, L | 1 |
| Hehlmann, R | 1 |
| Ho, AD | 1 |
| Hochhaus, A | 1 |
| Guerci, A | 1 |
| Merlin, JL | 1 |
| Missoum, N | 1 |
| Feldmann, L | 1 |
| Marchal, S | 1 |
| Witz, F | 1 |
| Rose, C | 1 |
| Guerci, O | 1 |
| Goldberg, J | 1 |
| Gryn, J | 1 |
| Raza, A | 1 |
| Bennett, J | 1 |
| Browman, G | 1 |
| Bryant, J | 1 |
| Grunwald, H | 1 |
| Larson, R | 1 |
| Vogler, R | 1 |
| Preisler, H | 1 |
| Talpaz, M | 2 |
| Kantarjian, H | 1 |
| Liang, J | 1 |
| Calvert, L | 1 |
| Hamer, J | 1 |
| Tibbits, P | 1 |
| Durett, A | 1 |
| Claxton, D | 1 |
| Giralt, S | 1 |
| Khouri, I | 1 |
| Liliemark, EK | 1 |
| Liliemark, J | 1 |
| Pettersson, B | 1 |
| Gruber, A | 2 |
| Peterson, C | 1 |
| Feldman, EJ | 2 |
| Alberts, DS | 1 |
| Arlin, Z | 2 |
| Ahmed, T | 1 |
| Mittelman, A | 1 |
| Baskind, P | 1 |
| Peng, YM | 1 |
| Baier, M | 1 |
| Plezia, P | 1 |
| Sundman-Engberg, B | 1 |
| Tidefelt, U | 1 |
| Paul, C | 1 |
| List, AF | 1 |
| Spier, CS | 1 |
| Grogan, TM | 1 |
| Johnson, C | 1 |
| Roe, DJ | 1 |
| Greer, JP | 1 |
| Wolff, SN | 1 |
| Broxterman, HJ | 1 |
| Scheffer, GL | 1 |
| Scheper, RJ | 1 |
| Dalton, WS | 1 |
| Lipton, JH | 1 |
| Messner, HA | 1 |
| Curtis, JE | 1 |
| Atkins, HL | 1 |
| Minden, MD | 1 |
| Martinelli, G | 1 |
| Testoni, N | 1 |
| Zuffa, E | 1 |
| Visani, G | 1 |
| Zinzani, PL | 1 |
| Zaccaria, A | 1 |
| Farabegoli, P | 1 |
| Arpinati, M | 1 |
| Amabile, M | 1 |
| Tura, S | 1 |
| Inukai, T | 1 |
| Sugita, K | 1 |
| Iijima, K | 1 |
| Goi, K | 1 |
| Tezuka, T | 1 |
| Kojika, S | 1 |
| Kagami, K | 1 |
| Mori, T | 1 |
| Kinoshita, A | 1 |
| Suzuki, T | 1 |
| O-Koyama, T | 1 |
| Nakazawa, S | 1 |
| Kanda, Y | 1 |
| Chiba, S | 1 |
| Honda, H | 1 |
| Hirai, H | 1 |
| Yazaki, Y | 1 |
| Koller, CA | 1 |
| Kantarjian, HM | 2 |
| O'Brien, S | 1 |
| Rios, MB | 1 |
| Estey, E | 1 |
| Keating, M | 1 |
| Robak, T | 1 |
| Góra-Tybor, J | 1 |
| Eudey, L | 1 |
| Bennett, JM | 1 |
| Kellermeyer, R | 1 |
| Rowe, J | 1 |
| O'Connell, M | 1 |
| Oken, M | 1 |
| Linkesch, W | 1 |
| Thaler, J | 1 |
| Gattringer, C | 1 |
| Konwalinka, G | 1 |
| Walters, RS | 1 |
| Keating, MJ | 1 |
| Andersson, B | 1 |
| Beran, M | 1 |
| McCredie, KB | 1 |
| Freireich, EJ | 1 |
| Heinemann, V | 1 |
| Murray, D | 1 |
| Walters, R | 1 |
| Meyn, RE | 1 |
| Plunkett, W | 1 |
| Okuma, K | 1 |
| Ariyoshi, Y | 1 |
| Ota, K | 1 |
| Sampi, K | 1 |
| Ogawa, M | 1 |
| Kimura, I | 1 |
| Ohnoshi, T | 1 |
| Yamada, K | 1 |
| Masaoka, T | 1 |
| Wakui, A | 1 |
| Meguro, S | 1 |
| Nagai, K | 1 |
| Kitani, T | 1 |
| Paciucci, PA | 1 |
| Keaveney, C | 1 |
| Cuttner, J | 1 |
| Holland, JF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia[NCT01690065] | Phase 2 | 46 participants (Anticipated) | Interventional | 2012-09-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mitoxantrone and Blast Phase
| Article | Year |
|---|---|
Long-term third chronic phase of chronic myelogenous leukemia maintained by interferon-alpha and methotrexate.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Etoposide; Humans; | 1999 |
10 trials available for mitoxantrone and Blast Phase
| Article | Year |
|---|---|
Homoharringtonine combined with cytarabine to treat chronic myelogenous leukemia in myeloid blast crisis and its impact on bone marrow CD34+CD7+ cells.
Topics: Adolescent; Adult; Antigens, CD34; Antigens, CD7; Antineoplastic Combined Chemotherapy Protocols; Bl | 2014 |
A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carboplatin; Female; Foll | 2010 |
Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Combined Moda | 2002 |
Treatment of blastic phase chronic myeloid leukemia with mitoxantrone, cytosine arabinoside and high dose methylprednisolone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Humans; Leu | 2002 |
Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Cytarabine; E | 2007 |
Mitoxantrone and 5-azacytidine for refractory/relapsed ANLL or CML in blast crisis: a leukemia intergroup study.
Topics: Adult; Azacitidine; Biopsy; Blast Crisis; Bone Marrow; Cell Cycle; DNA, Neoplasm; Female; Humans; Ka | 1993 |
Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Cr | 1993 |
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Cr | 1999 |
Cladribine combined with mitoxantrone in the treatment of blastic phase of chronic myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Blast Crisis; Cladribine; Drug Administration Schedule; Female; | 2001 |
Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; Drug Evaluat | 1992 |
17 other studies available for mitoxantrone and Blast Phase
| Article | Year |
|---|---|
Blast crisis of chronic myeloid leukemia: diagnosis prompted by T(8;9).
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplanta | 2002 |
Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Cells; CD13 | 2004 |
Gene expression profiles of two accelerations in a CML patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Gene Expression Pro | 2006 |
Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry.
Topics: Acute Disease; Adolescent; Adult; Aged; Antigens, CD; Antigens, CD34; Antineoplastic Combined Chemot | 1995 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Ce | 1995 |
In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia; relation to plasma concentrations and protein binding.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Blood Proteins; Cytarabin | 1993 |
Intracellular concentrations of mitoxantrone in leukemic cells in vitro vs in vivo.
Topics: Adult; Aged; Aged, 80 and over; Blast Crisis; Female; Humans; Intracellular Fluid; Leukemia, Myeloge | 1993 |
Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antigens, CD34; Antigens, CD7; Antineopla | 1996 |
Intensive remission induction therapy for chronic myeloid leukemia in blast phase with a goal of post-remission bone marrow transplant--a pilot study.
Topics: Adolescent; Adult; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone M | 1996 |
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantati | 1996 |
Leukemic cells with 11q23 translocations express granulocyte colony-stimulating factor (G-CSF) receptor and their proliferation is stimulated with G-CSF.
Topics: Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Blast Crisis; Cell Division; Cell Lin | 1998 |
Continuous infusion of mitoxantrone combined with high-dose cytarabine in refractory/relapsed acute myeloblastic leukemia and blast crisis of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemothe | 1990 |
Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Female; Humans; Leu | 1988 |
Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Ne | 1988 |
[Cardiotoxicity of mitoxantrone].
Topics: Adolescent; Adult; Aged; Blast Crisis; Child; Doxorubicin; Electrocardiography; Female; Heart; Heart | 1986 |
[Phase II trial of mitoxantrone in patients with relapsed and refractory acute leukemia].
Topics: Aclarubicin; Acute Disease; Adolescent; Adult; Aged; Blast Crisis; Child; Daunorubicin; Drug Evaluat | 1986 |
Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; | 1987 |